GCC Innovative Drug Discovery and Development Kickoff Mini-Symposium
The Innovative Drug Discovery and Development (IDDD) Consortium (formerly Chemical Genomics) invites you to join us for the kick-off of a new program and focus on supporting therapeutics advancement from discovery, through development, and to the clinic.
The event will begin at 8:30 am (breakfast at 8:00), and topics that will be discussed in the morning sessions include:
1) What are investors and/or pharma looking for in therapeutics?
2) How do they identify a good drug candidate?
3) What does it take to develop a successful therapeutic?
4) What can go wrong (challenges)?
5) Advice for moving academic discoveries into the clinic.
The lunch session will feature short introductions to the shared cores within the GCC IDDD network, and will be followed by onsite visits to several of the cores (transportation provided for those who sign up).
Confirmed Speakers:
Michelle Arkin, PhD
Professor, Pharmaceutical Chemistry
Co-Director, Small Molecule Discovery Center
University of California, San Francisco
President, Academic Drug Discovery Consortium
Phil Jones, PhD
Vice President, Therapeutics Discovery
MD Anderson Cancer Center; Head, Drug Discovery
Institute of Applied Cancer Science (IACS)
Lynn Johnson Langer, PhD, MBA
Executive Dean, Academic Programs at Foundation for Advanced Education in the Sciences at the NIH
Former Consultant and Executive Coach at Bioplan Associates, Inc.
Biotech Entrepreneur, Board Member, former CEO Opexa
Therapeutics
Gregory Stein, MD, MBA
President and CEO, Curtana Pharmaceuticals
C. Casey Cunningham, MD
Chief Scientific Officer, Santé Ventures
Connie Coulomb
Principal
Coulomb Strategy Consulting
Emily Reiser
Innovation Strategist
TMC Innovation